Why Werewolf Therapeutics stock exploded higher and what comes next?

Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the company has agreed to a definitive all-stock merger with Ambros Therapeutics.

The combined company will pivot to focus on Ambros' Phase 3 drug candidate – neridronate – for Complex Regional Pain Syndrome Type 1 (CRPS-1), backed by an oversubscribed $150 million private placement from top-tier institutional investors like RA Capital and Janus Henderson.

Despite the meteoric run on August 21, Werewolf shares remain down some 10% versus their year-to-date high.

Why Werewolf Therapeutics stock soared on Friday

The Ambros Therapeutics news follows an initial after-hours spike in HOWL shares late Thursday, when the company revealed the cash sale of its pre-clinical INDUCER and INDUKINE technology platforms to Merck KGaA subsidiary EMD Serono for $28 million upfront.

This immediately shored up Werewolf’s balance sheet with non-dilutive capital while maintaining rights to its clinical-stage programs, WTX-124 and WTX-330.

However, the major game-changer for shareholders is the merger with Ambros Therapeutics.

The transaction redefines the firm’s trajectory, establishing a well-capitalized entity that will trade under the new Nasdaq ticker symbol “AMBX” upon closing.

Crucially, the concurrent $150 million private placement provides a fully funded runway through the readout of the pivotal CRPS-RISE Phase 3 clinical trial expected in 2028 and subsequent NDA submission to the FDA.

For a micro-cap biotech stock previously trading near $0.40, securing an institutional-backed path toward commercialization removes near-term insolvency risks.

Is there any further upside left in WOLF shares?

While a 100%+ “single-day” surge often prompts fears of a “pump and dump” – several structural dynamics suggest the rally could hold substance, albeit with caveats.

Following the transaction, current Werewolf stockholders will retain about 6.8% ownership of the combined entity, reflecting a deal valuation that pegged HOWL at $47.5 million against Ambros’s $500 million valuation.

With Werewolf shares still trading below $1 – well under its 52-week peak of $2.38 – the market cap has only just recovered to around $44 million, meaning the stock remains discounted.

Plus, having institutional powerhouses lead a $150 million PIPE gives the joint entity significant Wall Street credibility.

Near-term upside may be capped by “arbitrage trading” and “dilution” as pre-funded warrants are factored in, but for long-term investors, gaining exposure to a fully funded late-stage Phase 3 pain management candidate offers a higher potential ceiling than Werewolf's former standalone status.

How to play Werewolf after the Ambros announcement

Looking past immediate intraday volatility, investors must recognize that Werewolf Therapeutics, as currently constituted, will effectively cease to exist once the transaction closes.

The executive leadership and headquarters will shift entirely to Ambros’ team in San Diego, CA, signifying a fundamental transition from an early-stage immuno-oncology player to a late-stage rare disease and chronic pain specialist.

The key catalyst for the next 12 to 24 months will no longer be early-stage oncology trial reads, but rather execution on enrollment for the CRPS-RISE Phase 3 trial.

Additionally, management will focus on obtaining necessary regulatory and shareholder approvals to finalize the corporate combination.

Shareholders who bought into the original immuno-oncology thesis must decide whether to take profits on Friday’s massive liquidity event or hold through the corporate transformation to participate in the commercialization attempt of neridronate.